Adam Olszewski
Brown University Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Olszewski as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07502872 · TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaBrown University · not yet recruiting · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:51 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.Nat Med · 2024103 citationsRCR 11.4
- Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.Blood · 201884 citationsRCR 4.0
- Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.Br J Haematol · 201978 citationsRCR 3.4
- Fish oil decreases serum homocysteine in hyperlipemic men.Coron Artery Dis · 199348 citationsRCR 2.0
- Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.J Clin Oncol · 202543 citationsRCR 9.8
- Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.Blood Adv · 202341 citationsRCR 3.3
- Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.J Clin Oncol · 202538 citationsRCR 7.8
- Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.Br J Haematol · 201837 citationsRCR 1.3
- The effects of dilute epinephrine saline irrigation on the need for tourniquet use in routine arthroscopic knee surgery.Am J Sports Med · 199921 citationsRCR 1.2
- The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.Am J Sports Med · 202019 citationsRCR 1.5